News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accessing the Regeneron (REGN) Second Quarter 2017 Financial And Operating Results Webcast



8/3/2017 12:42:23 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

TARRYTOWN, N.Y., Aug. 3, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Due to technical difficulties in accessing www.regeneron.com, the second quarter 2017 Financial and Operating Results webcast can be accessed at www.investor.regeneron.com or  http://edge.media-server.com/m/p/5wmatong beginning at 8:30 AM ET on Thursday, August 3rd, 2017.  To access this call, dial (888) 771-4371 (U.S.) or (847) 585-4405 (International). A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® which yields optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contacts Regeneron:


Media Relations                             

Investor Relations

Arleen Goldenberg                         

Manisha Narasimhan, Ph.D.

Tel: + 1 (914) 847-3456                     

Tel: +1 (914) 847-5126

Mobile: +1 (914) 260-8788                 

Manisha.narasimhan@regeneron.com         

arleen.goldenberg@regeneron.com  


 

View original content:http://www.prnewswire.com/news-releases/accessing-the-regeneron-second-quarter-2017-financial-and-operating-results-webcast-300499071.html

SOURCE Regeneron Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES